অস্ট্রেলিয়া - ইংরেজি - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - deracoxib - oral bolus, chewable - deracoxib anti-inflammatory-non-steroida active 25.0 mg/tb - musculoskeletal system - dog | bitch | castrate | puppy - analgesic | muscoskeletal discomfort | musculoskeletal conditions | orthopaedic - inflamation | antipyretic | arthritis | arthrosis | bursitis | colic | external myopathy | inflamation of soft tissues an | inflammation | muscle relaxant | osteitis | osteoarthritis | pain | sedative | spasmolytic | tendon and ligament sprains | tendonitis | tenosynovitis | traumatic joint and connective

কানাডা - ইংরেজি - Health Canada

elanco canada limited - deracoxib - tablet - 25mg - deracoxib 25mg - dogs

কানাডা - ইংরেজি - Health Canada

elanco canada limited - deracoxib - tablet - 100mg - deracoxib 100mg - dogs

কানাডা - ইংরেজি - Health Canada

elanco canada limited - deracoxib - tablet - 75mg - deracoxib 75mg - dogs

কানাডা - ইংরেজি - Health Canada

elanco canada limited - deracoxib - tablet - 12mg - deracoxib 12mg - dogs

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - alendronate sodium - tablet - 70 milligram(s) - bisphosphonates; alendronic acid - bisphosphonate, for the treatment of bone diseases - it is indicated in adults for the treatment of postmenopausal osteoporosis. fosamax reduces the risk of vertebral and hip fractures.

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - hydroxyzine hcl - tablet, film coated - 10 mg - hydroxyzine hcl 10 mg

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - hydroxyzine hcl - tablet, film coated - 25 mg - hydroxyzine hcl 25 mg

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

merck sharp & dohme corp. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alendronic acid 70 mg - fosamax® plus d is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax plus d is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.2)]. fosamax plus d alone should not be used to treat vitamin d deficiency. the optimal duration of use has not been determined. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. fosamax plus d is contraindicated in

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

physicians total care, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium 5 mg - fosamax is indicated for: - treatment and prevention of osteoporosis in postmenopausal women for the treatment of osteoporosis, fosamax increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (see clinical pharmacology, pharmacodynamics.) for the prevention of osteoporosis, fosamax may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. bone loss is particularly rapid in postmenopausal women younger than age 60. risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviatio